abstract of a thesis
Research purposes
In two phase III clinical studies, nivolumab significantly improved the overall survival of patients with advanced non-small cell lung cancer (NSCLC) compared with docetaxel. This study reports the follow-up results of a phase I clinical study of patients with advanced non-small cell lung cancer treated with nivolumab, and describes the characteristics of patients who have survived for 5 years.
research method
Patients with non-small cell lung cancer who had previously received multi-line systemic therapy were treated with 1mg/kg, 3mg/kg and 10mg/kg, once every two weeks, with a treatment cycle of 8 weeks, and the longest treatment time was 96 weeks. From the first administration, the OS of patients was evaluated by KM method.
research results
The 5-year survival rate of all patients treated with nivolumab was 16% (n = 129). The survival rate of squamous cell carcinoma (16%) is similar to that of adenocarcinoma (15%). Most of the 16 patients who survived for 5 years were former smokers or current smokers. Among the patients with quantifiable expression level of PD-L 1 0, the expression level of PD-L 1 at baseline was ≥ 1%. According to the criteria of RECIST v 1.0, 12 cases (75%) who survived for 5 years reached PR, and 2 cases in each group had the best curative effect. Nine patients completed the treatment for 96 weeks, four patients (25%) stopped treatment due to toxic side effects, and three patients (19%) stopped treatment due to PD. By the end of 20 16, 1 1 2 patients (75%) had not received follow-up treatment, and no evidence of disease progression was found at the last follow-up.
Research conclusion
Some patients with advanced non-small cell lung cancer can get long-term and sustained curative effect after treatment with nivolumab. Long-term survivors have different baseline and treatment characteristics.